Get 40% Off
💰 Buffett reveals a $6.7B stake in Chubb. Copy the full portfolio for FREE with InvestingPro’s Stock Ideas toolCopy Portfolio

UPDATE 1-Solvay misses out on Dutch H1N1 vaccine contract

Published 06/22/2009, 09:50 AM
Updated 06/22/2009, 09:57 AM
NOVN
-
SASY
-
SOLB
-

* Cannot supply vaccine within required timeframe

* Dutch government option still remains valid

* Solvay shares down 3.8 percent

(Adds spokesman's comments, details)

AMSTERDAM, June 22 (Reuters) - Belgium's Solvay said on Monday it missed out on a Dutch government contract to supply the Netherlands with an H1N1 flu virus vaccine because it could not supply the product within the required timeframe.

Solvay shares extended losses after Solvay's announcement and were down 3.8 percent at 57.93 euros at 1341 GMT, underperforming a 3 percent decline in the DJ Stoxx chemical index.

The Dutch government said last week it had bought 34 million vaccines from various vaccine makers, but did not identify which companies. It added that it had agreed with suppliers the vaccine had to be made available by the end of 2009.

"The Dutch government has placed its order with other vaccine producers as Solvay cannot deliver pandemic vaccines in the timeline asked by the Dutch government," Solvay spokesman Erik De Leye said.

But he added the option the Dutch government earlier placed with Solvay for the supply of a pandemic vaccine remained valid. That option had been placed with Solvay prior to the World Health Organisation declaring an influenza pandemic earlier this month. Other leading flu vaccine makers include Sanofi-Aventis, GlaxoSmithKline and Novartis.

There have been 105 people infected with the H1N1 virus in the Netherlands, but no deaths have been reported. (Reporting by Aaron Gray-Block; Editing by Jon Loades-Carter)

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.